Projects per year
Personal profile
Personal profile
Dr. Pingali is board certified by the American Board of Internal Medicine in medical oncology and hematology. His primary focus is on hematologic malignancies and stem cell transplantation. After completing his medical training in India, Dr. Pingali received training in various reputable programs in the United Kingdom as part of senior house officer training after which he moved to the United States. He completed his residency in internal medicine at Gundersen Lutheran Medical Center in Wisconsin. He then completed a fellowship in hematology and oncology at the Medical College of Wisconsin, and a fellowship in stem cell transplantation at the University of Texas MD Anderson Cancer Center.
Dr. Pingali is a member of the American Society of Clinical Oncology, American Society of Hematology and the American Society for Blood and Marrow Transplantation. He sees patients at Houston Methodist Hospital.
Research Area Keywords
- Cancer
- Clinical Translation & Trials
- Molecular Medicine
Fingerprint
- 1 Similar Profiles
Network
-
ER stress response and chronic lymphocytic leukemia
Hu, A., Pingali, S. R. & Tang, C. A.
9/3/21 → …
Project: Clinical Trial
-
Phase III_Parsaclisib and Ruxolitinib_Myelofibrosis_INCB 50465-313 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
Shah, S., Ganguly, S., Petkova, J., Pingali, S. R. & Rice, L.
8/23/21 → …
Project: Clinical Trial
-
Phase 3_NavitoclaxRuxolitinib_Myelofibrosis_Abbvie M20-178 Transform-2
Shah, S., Ganguly, S., Pingali, S. R. & Rice, L.
6/7/21 → …
Project: Clinical Trial
-
Targeting ER stress response in B-cell chronic lymphocytic leukemia
Hu, A., Pingali, S. R. & Tang, C. A.
4/1/21 → 3/31/24
Project: Federal Funding Agencies
-
CHEST CYTOSTORM study
Gotur, D. B., Chang, J. C., Pingali, S. R. & Rosato, R. R.
3/8/21 → …
Project: Clinical Trial
-
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
Su, P., Xiao, L., Ye, L., Wang, Z., Xiong, W., Wang, Q., Ma, X., Xian, M., Yang, M., Zu, Y., Pingali, S. R., Qian, J. & Yi, Q., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 55.Research output: Contribution to journal › Letter › peer-review
Open Access -
RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Wang, Q., Lin, Z., Wang, Z., Ye, L., Xian, M., Xiao, L., Su, P., Bi, E., Huang, Y. H., Qian, J., Liu, L., Ma, X., Yang, M., Xiong, W., Zu, Y., Pingali, S. R., Xu, B. & Yi, Q., Jan 6 2022, In: Blood. 139, 1, p. 59-72 14 p.Research output: Contribution to journal › Article › peer-review
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma
Friend, B. D., Muhsen, I. N., Patel, S., Hill, L. Q. C., Lulla, P., Ramos, C. A., Pingali, S. R., Kamble, R. T., John, T. D., Salem, B., Bhar, S., Doherty, E. E., Craddock, J., Sasa, G., Wu, M., Wang, T., Martinez, C., Krance, R. A., Heslop, H. E. & Carrum, G., Apr 2022, In: Bone Marrow Transplantation. 57, 4, p. 579-585 7 p.Research output: Contribution to journal › Article › peer-review
-
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma
Gentille, C., Sarfraz, H., Joshi, J., Randhawa, J., Shah, S. & Pingali, S. R., 2022, (Accepted/In press) In: Cancer Reports.Research output: Contribution to journal › Article › peer-review
Open Access -
G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
Youssef, J. G., Zahiruddin, F., Youssef, G., Padmanabhan, S., Ensor, J., Pingali, S. R., Zu, Y., Sahay, S. & Iyer, S. P., Mar 2021, In: Annals of Hematology. 100, 3, p. 667-673 7 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations